CoChat

Revolutionizing orthopedic healthcare: a systematic review unveiling recombinant antimicrobial peptides

Open access

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

Abstract

The increasing demand for orthopedic surgeries, including joint replacements, is driven by an aging population and improved diagnosis of joint conditions. Orthopedic surgeries carry a risk of infection, especially in patients with comorbidities. The rise of antibiotic resistance exacerbates this issue, necessitating alternatives like in vitro bioengineered antimicrobial peptides (AMPs), offering broad-spectrum activity and multiple action mechanisms. This review aimed to assess the prevalence of antimicrobial potential and the yield after purification among recombinant AMP families. The antimicrobial potential was evaluated using the Minimum Inhibitory Concentration (MIC) values against the most common bacteria involved in clinical infections. This systematic review adhered to PRISMA guidelines, focusing on in vitro studies of recombinant AMPs. The search strategy was run on PubMed, Scopus and Embase up to 30 th March 2023. The Population, Exposure and Outcome model was used to extract the data from studies and ToxRTool for the risk of bias analysis. This review included studies providing peptide production yield data and MIC values against pathogenic bacteria. Non-English texts, reviews, conference abstracts, books, studies focusing solely on chemical synthesis, those reporting incomplete data sets, using non-standard MIC assessment methods, or presenting MIC values as ranges rather than precise concentrations, were excluded. From 370 publications, 34 studies on AMPs were analyzed. These covered 46 AMPs across 18 families, with Defensins and Hepcidins being most common. Yields varied from 0.5 to 2,700 mg/L. AMPs were tested against 23 bacterial genera, with MIC values ranging from 0.125 to >1,152 μg/mL. Arenicins showed the highest antimicrobial activity, particularly against common orthopedic infection pathogens. However, AMP production yields varied and some AMPs demonstrated limited effectiveness against certain bacterial strains. This systematic review emphasizes the critical role of bioengineered AMPs to cope infections and antibiotic resistance. It meticulously evaluates recombinant AMPs, focusing on their antimicrobial efficacy and production yields. The review highlights that, despite the variability in AMP yields and effectiveness, Arenicins and Defensins are promising candidates for future research and clinical applications in treating antibiotic-resistant orthopedic infections. This study contributes significantly to the understanding of AMPs in healthcare, underscoring their potential in addressing the growing challenge of antibiotic resistance. Systematic review registration:https://osf.io/2uq4c/.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmicb.2024.1370826

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic flow chart of the systematic review. The figure presents a detailed flow chart outlining the methodology from the data search to extraction. Outcomes include the selected studies highlighting the range values of yield and MIC. The figure also depicts the results, quantified by the number of selected studies, of the predominant AMP families against the three primary bacteria genera responsible for orthopedic infections. Created with BioRender.com.
Figure 1 Schematic flow chart of the systematic review. The figure presents a detailed flow chart outlining the methodology from the data search to extraction. Outcomes include the selected studies highlighting the range values of yield and MIC. The figure also depicts the results, quantified by the number of selected studies, of the predominant AMP families against the three primary bacteria genera responsible for orthopedic infections. Created with BioRender.com.CC BY · PubMed Central
Figure 2 This figure illustrates the meticulous process undertaken to select studies for inclusion in our review, emphasizing our commitment to transparency and rigor. The PRISMA flow began with a comprehensive search and meticulous screening of a vast literature. After removing non-compliant studies, the data from 34 publications were extracted for the further steps of this review.
Figure 2 This figure illustrates the meticulous process undertaken to select studies for inclusion in our review, emphasizing our commitment to transparency and rigor. The PRISMA flow began with a comprehensive search and meticulous screening of a vast literature. After removing non-compliant studies, the data from 34 publications were extracted for the further steps of this review.CC BY · PubMed Central
Figure 3 A classification of the AMP families described in the selected literature is represented, which serves as a demonstration of the diversity and complexity of these molecules. AMP families are ranked based on the total number of MIC values reported. The corresponding genus of the bacteria tested is also represented and the alluvial chart shows the connection between AMP families and microbe genus. This general categorization was used to select the most represented AMP families and targeted microorganisms.
Figure 3 A classification of the AMP families described in the selected literature is represented, which serves as a demonstration of the diversity and complexity of these molecules. AMP families are ranked based on the total number of MIC values reported. The corresponding genus of the bacteria tested is also represented and the alluvial chart shows the connection between AMP families and microbe genus. This general categorization was used to select the most represented AMP families and targeted microorganisms.CC BY · PubMed Central
Figure 4 The alluvial chart visually describes the Hepcidins family by tracing their journey from production yield to their microbial targets and effectiveness. Starting from the left, the chart records the yield of each Hepcidin in mg/L, illustrating the diversity in production efficiency among the family members. This flows into the central section, which outlines the various bacterial genera targeted by these peptides, highlighting the broad spectrum of their antimicrobial activity. On the right, the minimum inhibitory concentration (MIC) range in μg/mL is reported, describing the antimicrobial activity of Hepcidins against these bacterial targets. A unique color is assigned to each AMP, thereby enabling readers to follow the story of each peptide across the chart. This figure provides a comprehensive overview of the Hepcidins’ antimicrobial capabilities and emphasizes the potential of these peptides in developing new antibacterial therapies.
Figure 4 The alluvial chart visually describes the Hepcidins family by tracing their journey from production yield to their microbial targets and effectiveness. Starting from the left, the chart records the yield of each Hepcidin in mg/L, illustrating the diversity in production efficiency among the family members. This flows into the central section, which outlines the various bacterial genera targeted by these peptides, highlighting the broad spectrum of their antimicrobial activity. On the right, the minimum inhibitory concentration (MIC) range in μg/mL is reported, describing the antimicrobial activity of Hepcidins against these bacterial targets. A unique color is assigned to each AMP, thereby enabling readers to follow the story of each peptide across the chart. This figure provides a comprehensive overview of the Hepcidins’ antimicrobial capabilities and emphasizes the potential of these peptides in developing new antibacterial therapies.CC BY · PubMed Central
Figure 5 The alluvial chart visually describes the Arenicins family by tracing their journey from production yield through to their microbial targets and effectiveness. Starting from the left, the chart records the yield of each Arenicin in mg/L, illustrating the diversity in production efficiency among the family members. This flows into the central section, which outlines the various bacterial genera targeted by these peptides, highlighting the broad spectrum of their antimicrobial activity. On the right, the minimum inhibitory concentration (MIC) range in μg/mL is reported, describing the antimicrobial activity of Arenicins against these bacterial targets. A unique color is assessed to each AMP, thereby enabling readers to follow the story of each peptide across the chart. This figure provides a comprehensive overview of the Arenicins’ antimicrobial capabilities and emphasizes the potential of these peptides in developing new antibacterial therapies.
Figure 5 The alluvial chart visually describes the Arenicins family by tracing their journey from production yield through to their microbial targets and effectiveness. Starting from the left, the chart records the yield of each Arenicin in mg/L, illustrating the diversity in production efficiency among the family members. This flows into the central section, which outlines the various bacterial genera targeted by these peptides, highlighting the broad spectrum of their antimicrobial activity. On the right, the minimum inhibitory concentration (MIC) range in μg/mL is reported, describing the antimicrobial activity of Arenicins against these bacterial targets. A unique color is assessed to each AMP, thereby enabling readers to follow the story of each peptide across the chart. This figure provides a comprehensive overview of the Arenicins’ antimicrobial capabilities and emphasizes the potential of these peptides in developing new antibacterial therapies.CC BY · PubMed Central
Figure 6 The alluvial chart visually describes the Defensins family by tracing their journey from production yield through to their microbial targets and effectiveness. Starting from the left, the chart records the yield of each Defensin in mg/L, illustrating the diversity in production efficiency among the family members. This flows into the central section, which outlines the various bacterial genera targeted by these peptides, highlighting the broad spectrum of their antimicrobial activity. On the right, the minimum inhibitory concentration (MIC) range in μg/mL is reported, describing the antimicrobial activity of Defensins against these bacterial targets. A unique color is assessed to each AMP, thereby enabling readers to follow the story of each peptide across the chart. This figure provides a comprehensive overview of the Defensins’ antimicrobial capabilities and emphasizes the potential of these peptides in developing new antibacterial therapies.
Figure 6 The alluvial chart visually describes the Defensins family by tracing their journey from production yield through to their microbial targets and effectiveness. Starting from the left, the chart records the yield of each Defensin in mg/L, illustrating the diversity in production efficiency among the family members. This flows into the central section, which outlines the various bacterial genera targeted by these peptides, highlighting the broad spectrum of their antimicrobial activity. On the right, the minimum inhibitory concentration (MIC) range in μg/mL is reported, describing the antimicrobial activity of Defensins against these bacterial targets. A unique color is assessed to each AMP, thereby enabling readers to follow the story of each peptide across the chart. This figure provides a comprehensive overview of the Defensins’ antimicrobial capabilities and emphasizes the potential of these peptides in developing new antibacterial therapies.CC BY · PubMed Central
Figure 7 The alluvial chart visually describes the ALFs family by tracing their journey from production yield through to their microbial targets and effectiveness. Starting from the left, the chart records the yield of each ALF in mg/L, illustrating the diversity in production efficiency among the family members. This flows into the central section, which outlines the various bacterial genera targeted by these peptides, highlighting the broad spectrum of their antimicrobial activity. On the right, the minimum inhibitory concentration (MIC) range in μg/mL is reported, describing the antimicrobial activity of ALFs against these bacterial targets. A unique color is assessed to each AMP, thereby enabling readers to follow the story of each peptide across the chart. This figure provides a comprehensive overview of the ALFs’ antimicrobial capabilities and emphasizes the potential of these peptides in developing new antibacterial therapies.
Figure 7 The alluvial chart visually describes the ALFs family by tracing their journey from production yield through to their microbial targets and effectiveness. Starting from the left, the chart records the yield of each ALF in mg/L, illustrating the diversity in production efficiency among the family members. This flows into the central section, which outlines the various bacterial genera targeted by these peptides, highlighting the broad spectrum of their antimicrobial activity. On the right, the minimum inhibitory concentration (MIC) range in μg/mL is reported, describing the antimicrobial activity of ALFs against these bacterial targets. A unique color is assessed to each AMP, thereby enabling readers to follow the story of each peptide across the chart. This figure provides a comprehensive overview of the ALFs’ antimicrobial capabilities and emphasizes the potential of these peptides in developing new antibacterial therapies.CC BY · PubMed Central
Figure 8 In orthopedic infections, three bacteria genera are the most represented (Staphylococcus, Pseudomonas and Escherichia). The alluvial chart illustrates the efficacy of various AMP families (on the left side: Arenicins, Defensins, ALFs, and Hepcidins) in inhibiting these bacteria genera. On the right side of the chart, minimum inhibitory concentration (MIC) values are categorized as either greater than (>) or less than or equal to (≤) the 75th percentile, with the following thresholds: Arenicins at 10 μg/mL, Defensins at 65.6 μg/mL, ALFs at 318 μg/mL, and Hepcidins at 436.5 μg/mL. The legend at the bottom shows each AMP considered in the chart.
Figure 8 In orthopedic infections, three bacteria genera are the most represented (Staphylococcus, Pseudomonas and Escherichia). The alluvial chart illustrates the efficacy of various AMP families (on the left side: Arenicins, Defensins, ALFs, and Hepcidins) in inhibiting these bacteria genera. On the right side of the chart, minimum inhibitory concentration (MIC) values are categorized as either greater than (>) or less than or equal to (≤) the 75th percentile, with the following thresholds: Arenicins at 10 μg/mL, Defensins at 65.6 μg/mL, ALFs at 318 μg/mL, and Hepcidins at 436.5 μg/mL. The legend at the bottom shows each AMP considered in the chart.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 2024, The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Disk diffusion method for antimicrobial susceptibility testing, version 12.0. 2024

Cited by

See all 9

Metadata

Authors
Pennone, V., Rosini, E., Mascheroni, E., Gianola, S., Castellini, G., Bargeri, S., & Lovati, A. B.
Affiliations
  • IRCCS Ospedale Galeazzi - Sant'Ambrogio (IT)
  • University of Insubria (IT)
Corresponding author
Pennone, Vincenzo
Venue
Frontiers in Microbiology
Published
2024-04-29
Volume
15
Pages
1370826-1370826
ISSN
1664-302X (ISSN-L)
OpenAlex
W4396241622
Cited by
8
References
89
Citations by year
2026: 3 · 2025: 3 · 2024: 2
FWCI
0.41
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Microbiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IrInSubria (University of Insubria) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Ministero della Salute
  • Università degli Studi dell'Insubria
  • Regione Lombardia
  • Fondazione Regionale per la Ricerca Biomedica (3414083 AMPROject, 3414083)
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
  • Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antimicrobial agents and applications
  • Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
Keywords
bone and joint infections, antibiotic resistance, minimum inhibitory concentration, defensins, hepcidin, pathogenic bacteria

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.